Status of basal-supported oral therapy in Chinese XXXX 2 @entity6 @entity1 with inadequate glycemic control on oral anti- @entity6 drugs.

@entity1 @entity6 @entity2690 @entity164 @entity413
BACKGROUND: Timely initiation and titration of basal @entity2690 added on to oral anti- @entity6 drugs contribute to better glycemic control. However, implementation of basal-supported oral therapy in China is not yet clear. This nationwide, prospective, 12-week observational study was designed to explore the current status of basal-supported oral therapy in @entity1 with @entity164 2 @entity6 in China. METHODS: Type 2 @entity6 @entity1 with inadequate glycemic control on anti- @entity6 drugs who were to start basal-supported oral therapy with @entity2690 glargine at outpatient clinics were enrolled from 134 hospitals in China. Both the decision to initiate basal @entity2690 and @entity2690 dose adjustment were at the physician's discretion. Fasting plasma @entity413 (FPG) and haemoglobin A1c were measured, and the starting dose of @entity2690 were recorded at baseline. Self-monitored fasting capillary blood @entity413 and the adjusting dose of @entity2690 were collected during the study. RESULTS: A total of 11  192 out of 13  259 enrolled @entity1 finished the 12-week study. FPG and haemoglobin A1c at basal-supported oral therapy initiation were 11.2  mmol/L and 9.4%, respectively, with @entity2690 glargine started at 0.190  IU/kg/day. @entity2690 dose was increased 1.8  IU in average within 12 weeks. Fifty-nine percent of the @entity1 achieved fasting capillary blood @entity413  <= 7.0  mmol/L. More @entity1 achieved the @entity413 target in the group with lower baseline FPG level. Notable geographical differences of physicians' treatment habits in the current management of basal-supported oral therapy were also observed. CONCLUSIONS: A great gap between everyday clinical practice and guidelines exists in China, reflected by the delayed initiation, slow dose titration and geographical differences of basal-supported oral therapy management. A concrete guideline of basal-supported oral therapy management is needed in the clinical application. Copyright    2015 John Wiley _ Sons, Ltd.
